<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689114</url>
  </required_header>
  <id_info>
    <org_study_id>STANDLOW</org_study_id>
    <nct_id>NCT03689114</nct_id>
  </id_info>
  <brief_title>Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)</brief_title>
  <acronym>STANDLOW</acronym>
  <official_title>Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no guidelines on the first maintenance daily dose of antiepileptic drugs (AEDs) in
      newly diagnosed, previously untreated epilepsy. Original trials and Cochrane reviews show
      that seizure remission can be achieved with differing daily doses. In clinical practice, the
      first maintenance dose varies significantly. In contrast, the risk of adverse treatment
      effects increases with dosage. There is thus the need to identify the lowest effective dose
      for treatment start. This background prompted us to undertake a randomized multicenter
      pragmatic non-inferiority trial comparing standard to low daily doses of AEDs to demonstrate
      that low doses are at least as effective as standard doses (as indicated by the national
      formulary) but are better tolerated and are associated with a better quality of life. If
      proven as effective as the standard dose, a low daily dose of AEDs is a benefit to the
      patient in terms of tolerability and safety and a source of savings for the National Health
      System.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 7, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multicenter randomized pragmatic parallel-group single-blind non-inferiority trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of patients experiencing a treatment failure motivated by the need to change the assigned dose or the assigned drug for seizure relapse during the follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>the proportion of patients experiencing a treatment failure motivated by intolerable drug-related adverse events during the follow-up;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in epilepsy scale 31 items(QOLIE-31), italian version</measure>
    <time_frame>12 months</time_frame>
    <description>QOLIE-31 total score at baseline and last visit. Maximum total score is 100 (best quality of life possible) and the minimum is 0 (worst quality of life possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients health care's satisfaction (PSQ-18) scale, 18 items</measure>
    <time_frame>12 months</time_frame>
    <description>The score of the seven PSQ-18 subscales (general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, accessibility and convenience) at baseline and last visit. Possible scores of each subscale range from 1 (worst satisfaction) to 5 (better satisfaction). There is no total score for this scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care resources utilization.</measure>
    <time_frame>12 months</time_frame>
    <description>The mean daily patient's cost of health care resources consumed for the management of epilepsy during the first 12 months of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Epilepsies, Partial</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage is in mg: low dose carbamazepine, 300 ; low dose levetiracetam, 500; low dose valproate, 300; low dose zonisamide, 150; low dose oxcarbazepine, 600; low dose topiramate, 100; low dose lamotrigine, 100; low dose gabapentin, 450. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage is in mg: standard dose carbamazepine 600; standard dose levetiracetam 1000; standard dose valproate, 600; standard dose zonisamide 300; standard dose oxcarbazepine 1200; standard dose topiramate, 200; standard dose lamotrigine, 200; standard dose gabapentin 900. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose carbamazepine</intervention_name>
    <description>Carbamazepine, 300 mg/die</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>low carbamazepine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose carbamazepine</intervention_name>
    <description>Carbamazepine 600 mg/die</description>
    <arm_group_label>Standard dose</arm_group_label>
    <other_name>Standard carbamazepine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose levetiracetam</intervention_name>
    <description>Levetiracetam 500 mg/die</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Low levetiracetam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose levetiracetam</intervention_name>
    <description>Levetiracetam 1000 mg/die</description>
    <arm_group_label>Standard dose</arm_group_label>
    <other_name>Standard levetiracetam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose valproate</intervention_name>
    <description>Valproate 300 mg/die</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Low valproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose valproate</intervention_name>
    <description>Valproate 600 mg/die</description>
    <arm_group_label>Standard dose</arm_group_label>
    <other_name>Standard valproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose zonisamide</intervention_name>
    <description>Zonisamide 150 mg/die</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Low zonisamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose zonisamide</intervention_name>
    <description>Zonisamide 300 mg/die</description>
    <arm_group_label>Standard dose</arm_group_label>
    <other_name>Standard zonisamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose oxcarbazepine</intervention_name>
    <description>Oxcarbazepine 600 mg/die</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Low oxcarbazepine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose oxcarbazepine</intervention_name>
    <description>Oxcarbazepine 1200 mg/die</description>
    <arm_group_label>Standard dose</arm_group_label>
    <other_name>Standard oxcarbazepine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose topiramate</intervention_name>
    <description>Topiramate 100 mg/die</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Low topiramate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose topiramate</intervention_name>
    <description>Topiramate 200 mg/die</description>
    <arm_group_label>Standard dose</arm_group_label>
    <other_name>Standard topiramate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose lamotrigine</intervention_name>
    <description>Lamotrigine 100 mg/die</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Low lamotrigine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose lamotrigine</intervention_name>
    <description>Lamotrigine 200 mg/die</description>
    <arm_group_label>Standard dose</arm_group_label>
    <other_name>Standard lamotrigine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose gabapentin</intervention_name>
    <description>Gabapentin 450 mg/die</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Low gabapentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose gabapentin</intervention_name>
    <description>Gabapentin 900 mg/die</description>
    <arm_group_label>Standard dose</arm_group_label>
    <other_name>Standard gabapentin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older;

          2. Newly diagnosed previously untreated epilepsy, defined according to the ILAE
             definition (Fisher et al, 2014);

          3. Having experienced focal seizures, defined according to the ILAE criteria (Commission,
             1981);

          4. Able to understand and comply with the study requirements and release a written
             informed consent.

        Exclusion Criteria:

        A patient will be excluded if at least one of the following criteria will be met:

          1. Age less than 18 years;

          2. Having experienced primarily or secondarily generalized tonic and/or clonic seizures,
             or other (non-focal) seizure types;

          3. Previous exposure to AEDs;

          4. Requiring low or standard doses on account of individual needs;

          5. Inability to understand the aims or modalities of the study;

          6. Current pregnancy or planning to become pregnant during the study period (e.g. who are
             not post-menopausal, surgically sterile, or using inadequate birth control). A
             postmenopausal state is defined as no menses for 12 months without an alternative
             medical cause;

          7. Previous treatment with an antiepileptic drug;

          8. Men unable to practice contraception for the duration of the treatment.

          9. Poor compliance with assigned treatments;

         10. Refusal to release written informed consent;

         11. The study investigators will receive the summary of product characteristics (SPC)
             available for each study drug. Patients cannot be enrolled in the study if the
             contraindications/warnings described in the SPC are met.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ettore Beghi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ettore Beghi, MD</last_name>
    <phone>0239014542</phone>
    <email>ettore.beghi@marionegri.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giorgia Giussani, PhD</last_name>
    <phone>0239014604</phone>
    <email>giorgia.giussani@marionegri.it</email>
  </overall_contact_backup>
  <reference>
    <citation>Abimbola S, Martiniuk AL, Hackett ML, Anderson CS. The influence of design and definition on the proportion of general epilepsy cohorts with remission and intractability. Neuroepidemiology. 2011;36(3):204-12. doi: 10.1159/000327497. Epub 2011 May 24. Review.</citation>
    <PMID>21606654</PMID>
  </reference>
  <reference>
    <citation>Beghi E, Niero M, Roncolato M. Validity and reliability of the Italian version of the Quality-of-Life in Epilepsy Inventory (QOLIE-31). Seizure. 2005 Oct;14(7):452-8. Epub 2005 Aug 10.</citation>
    <PMID>16098770</PMID>
  </reference>
  <reference>
    <citation>Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1981 Aug;22(4):489-501.</citation>
    <PMID>6790275</PMID>
  </reference>
  <reference>
    <citation>Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Mosh√© SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82. doi: 10.1111/epi.12550. Epub 2014 Apr 14. Review.</citation>
    <PMID>24730690</PMID>
  </reference>
  <reference>
    <citation>Gilliam F. Optimizing health outcomes in active epilepsy. Neurology. 2002 Apr 23;58(8 Suppl 5):S9-20. Review.</citation>
    <PMID>11971128</PMID>
  </reference>
  <reference>
    <citation>Maguire M, Marson AG, Ramaratnam S. Epilepsy (partial). BMJ Clin Evid. 2010 Jun 28;2010. pii: 1214. Review.</citation>
    <PMID>21429248</PMID>
  </reference>
  <reference>
    <citation>Perucca P, Jacoby A, Marson AG, Baker GA, Lane S, Benn EK, Thurman DJ, Hauser WA, Gilliam FG, Hesdorffer DC. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology. 2011 Jan 18;76(3):273-9. doi: 10.1212/WNL.0b013e318207b073.</citation>
    <PMID>21242496</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>antiepileptic drugs</keyword>
  <keyword>low dose</keyword>
  <keyword>standard dose</keyword>
  <keyword>new diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Zonisamide</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Oxcarbazepine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Levetiracetam</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

